Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - VIROPHARMA INC | d231662dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): September 13, 2011
VIROPHARMA INCORPORATED
(Exact Name of Registrant as Specified in its Charter)
DELAWARE | 0-021699 | 23-2789550 | ||
(State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) | ||
730 STOCKTON DRIVE, EXTON, PENNSYLVANIA | 19341 | |||
(Address of Principal Executive Offices) | (Zip Code) |
(610) 458-7300
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Item 8.01. Other Events.
On September 13, 2011, ViroPharma Incorporated and Halozyme Therapeutics issued a press release to announce that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1esterase inhibitor [human)] in combination with Halozymes proprietary Enhanze technology, a proprietary drug delivery platform using Halozymes recombinant human hyaluronidase enzyme (rHuPH20), in subjects with hereditary angioedema (HAE). Initiation of the clinical trial has triggered a milestone payment of $3 million to Halozyme.
The full text of a press release issued by the Company in connection with the announcement is set forth as Exhibit 99.1 attached hereto.
Item 9.01 Financial Statements and Exhibits.
The following exhibits are attached to this Form 8-K:
(d) | Exhibit No. |
Description | ||
99.1 | Press release dated September 13, 2011. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VIROPHARMA INCORPORATED | ||||||
Date: September 13, 2011 | By: | /s/ J. Peter Wolf J. Peter Wolf Vice President, General Counsel and Secretary | ||||
Index of Exhibits
Exhibit |
Description | |
99.1 | Press release dated September 13, 2011. |